<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00942851</url>
  </required_header>
  <id_info>
    <org_study_id>090193</org_study_id>
    <secondary_id>09-N-0193</secondary_id>
    <nct_id>NCT00942851</nct_id>
  </id_info>
  <brief_title>A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm</brief_title>
  <official_title>A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BCN Peptides</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

        -  Blepharospasm is caused by excessive contraction of the muscles that close the eye. It
           can be treated with injections of botulinum neurotoxin (BoNT), which works by weakening
           those muscles.

        -  Acetyl Hexapeptide-8 (AH-8) is the active ingredient in a number of cosmetic creams used
           to treat wrinkles, and is marketed under the trade name Argireline(Copyright). Like
           BoNT, AH-8 works to weaken the muscles, but is available as a skin cream instead of an
           injection. AH-8 has never been used to treat people with blepharospasm.

      Objectives:

      - To determine if AH-8 can be used as part of a treatment regimen for blepharospasm.

      Eligibility:

      - Individuals 18 years of age and older who have blepharospasm and have been receiving
      successful treatment with botulinum toxin injections.

      Design:

        -  Participants will be involved in the study for a maximum of 7 months.

        -  Patients will have a complete physical and neurological exam, and will be asked
           questions about their blepharospasm. Patients will then receive BoNT injections in the
           same areas of the muscle around the eye and at the same doses that have been effective
           previously.

        -  After the injections, patients will receive a container of either the active cream (with
           AH-8) or cream without AH-8, and will be instructed on how to apply it.

        -  Patients will return 1 month after the first visit for another neurologic exam and
           questions, and will be asked about any side effects. Another supply of cream will be
           given.

        -  Five additional visits will take place on a monthly basis, and patients will be given
           additional supplies of the cream as needed. Patients will stop participating in the
           study if they require another BoNT injection for blepharospasm. The study will end after
           7 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE:

      To study the efficacy of cutaneous application of Acetyl Hexapeptide-8 (AH8) in the therapy
      of blepharospasm.

      STUDY POPULATION:

      22 patients with blepharospasm.

      DESIGN:

      This will be a double blind, placebo-controlled trial. Patients receiving treatment of
      blepharospasm with botulinum neurotoxin (BoNT) will be recruited. They will receive either
      the study substance or a placebo cream containing the emulsion but no active substance, in
      twice daily applications to the eyelids beginning the day following a BoNT injection
      treatment. They will continue to apply the cream and we will record the time until their
      condition worsens back to baseline following benefit from the injections, hypothesizing that
      the cream application will prolong the time until the need for the next injection by at least
      3 months.

      OUTCOME MEASURES::

      Primary: time until the Jankovic Blepharospasm Rating Scale (JBRS) reverts back to baseline.

      Secondary: Change in the JBRS at 6 months; Change in the JBRS at 7 months if not receiving
      BoNT; Change in the JBRS at 3 months; Change in the Blepharospasm Disability Scale at 6
      months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time Until Jankovic Blepharospasm Rating Scale (JBRS) Reverts Back to Baseline</measure>
    <time_frame>3-7 months</time_frame>
    <description>The JBRS is a severity scale for blepharospasm, ranging from 0 (no symptoms) to 8 (the most severe symptoms, functionally blind). It includes measures of blink frequency and severity of abnormal eye closure. The scale was measured at baseline (before intervention) and followed over time. Return to baseline value represents loss of benefit from BoNT injection. The time to return to baseline JBRS is an indication of added benefit from the topical intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the JBRS at 3 Months</measure>
    <time_frame>baseline to 3 months</time_frame>
    <description>The JBRS is a severity scale for blepharospasm, ranging from 0 (no symptoms) to 8 (the most severe symptoms, functionally blind). It includes measures of blink frequency and severity of abnormal eye closure. The scale was measured at baseline (before intervention) and followed over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Blepharospasm Disability Scale (BDS) Change at 3 Months</measure>
    <time_frame>baseline to 3 months</time_frame>
    <description>% BDS change at 3 months. The BDS is a quality of life scale ranging from 0 (no symptoms) to 26 (maximum impact of symptoms on quality of life). The questions are specific for impairment related to blepharospasm. We compared the percentage change over three months in the active and placebo arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Focal Dystonia</condition>
  <arm_group>
    <arm_group_label>active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AH-8 containing topical intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>topical intervention WITHOUT AH-8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetyl-Hexapeptide Topical Treatment</intervention_name>
    <description>AH-8 containing topical treatment</description>
    <arm_group_label>active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>topical treatment NOT containing AH-8</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Age above 18 years

               2. Diagnosis of PB made by a Movement Disorders Neurologist

               3. Severity of PB prompting the need for treatment as determined by patient
                  subjective assessment.

               4. JBRS of at least 3 at initial visit.

               5. BDS of at least 8 at the entry visit.

               6. At least three prior successful injectable BoNT treatments, with stable interval
                  between injections of 3 months (ie duration of response of 3 months).

        EXCLUSION CRITERIA:

          1. Pregnant women

          2. Blepharospasm associated with a different Neurologic condition, including but not
             limited to generalyzed dystonia, a parkinsonian syndrome, or major brain structural
             abnormality, as evidenced by Neurologic exam and/or review of records

          3. Skin condition resulting in loss of integrity of the skin overlying the OO or
             potentially interfering with cream absorption.

          4. Medical condition impairing the patient's ability to comply with the study protocol or
             to perform daily applications of the cream as instructed

          5. Abnormally long or short response to BoNT treatment in the past, ie duration of PB
             relief with BoNT greater than 4 months or less than 2 months.

          6. Allergy to any component of the study or placebo cream.

          7. Known or observed eye pathology.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ben Simon GJ, McCann JD. Benign essential blepharospasm. Int Ophthalmol Clin. 2005 Summer;45(3):49-75. Review.</citation>
    <PMID>15970766</PMID>
  </reference>
  <reference>
    <citation>Defazio G, Livrea P. Primary blepharospasm: diagnosis and management. Drugs. 2004;64(3):237-44. Review.</citation>
    <PMID>14871168</PMID>
  </reference>
  <reference>
    <citation>Defazio G, Livrea P. Epidemiology of primary blepharospasm. Mov Disord. 2002 Jan;17(1):7-12. Review.</citation>
    <PMID>11835433</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2009</study_first_submitted>
  <study_first_submitted_qc>July 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2009</study_first_posted>
  <results_first_submitted>May 29, 2012</results_first_submitted>
  <results_first_submitted_qc>August 3, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 6, 2012</results_first_posted>
  <last_update_submitted>August 3, 2012</last_update_submitted>
  <last_update_submitted_qc>August 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dystonia</keyword>
  <keyword>Blepharospasm</keyword>
  <keyword>Botulinum Toxin</keyword>
  <keyword>Treatment</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Focal Dystonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Blepharospasm</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active</title>
          <description>Topical intervention agent containing AH8 0.005% Twice daily application to the eyelids in standardized fashion.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Topical intervention agent WITHOUT AH-8. Identically appearing cream without the active ingredient.
Twice daily application to the eyelids in standardized fashion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>AH-8 containing topical intervention</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>topical intervention WITHOUT AH-8</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.59" spread="8.46"/>
                    <measurement group_id="B2" value="55.87" spread="8.25"/>
                    <measurement group_id="B3" value="56.73" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time Until Jankovic Blepharospasm Rating Scale (JBRS) Reverts Back to Baseline</title>
        <description>The JBRS is a severity scale for blepharospasm, ranging from 0 (no symptoms) to 8 (the most severe symptoms, functionally blind). It includes measures of blink frequency and severity of abnormal eye closure. The scale was measured at baseline (before intervention) and followed over time. Return to baseline value represents loss of benefit from BoNT injection. The time to return to baseline JBRS is an indication of added benefit from the topical intervention.</description>
        <time_frame>3-7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Ingredient- AH8</title>
            <description>subjects receiving active intervention, ie topical cream containing 0.005% AH-8</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>subjects receiving placebo intervention, ie identically-appearing topical cream without AH-8 content</description>
          </group>
        </group_list>
        <measure>
          <title>Time Until Jankovic Blepharospasm Rating Scale (JBRS) Reverts Back to Baseline</title>
          <description>The JBRS is a severity scale for blepharospasm, ranging from 0 (no symptoms) to 8 (the most severe symptoms, functionally blind). It includes measures of blink frequency and severity of abnormal eye closure. The scale was measured at baseline (before intervention) and followed over time. Return to baseline value represents loss of benefit from BoNT injection. The time to return to baseline JBRS is an indication of added benefit from the topical intervention.</description>
          <units>month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" spread="1.48"/>
                    <measurement group_id="O2" value="3.03" spread=".23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the JBRS at 3 Months</title>
        <description>The JBRS is a severity scale for blepharospasm, ranging from 0 (no symptoms) to 8 (the most severe symptoms, functionally blind). It includes measures of blink frequency and severity of abnormal eye closure. The scale was measured at baseline (before intervention) and followed over time.</description>
        <time_frame>baseline to 3 months</time_frame>
        <population>One placebo arm participant dropped out due to unrelated personal problems</population>
        <group_list>
          <group group_id="O1">
            <title>Active Ingredient- AH8</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Change in the JBRS at 3 Months</title>
          <description>The JBRS is a severity scale for blepharospasm, ranging from 0 (no symptoms) to 8 (the most severe symptoms, functionally blind). It includes measures of blink frequency and severity of abnormal eye closure. The scale was measured at baseline (before intervention) and followed over time.</description>
          <population>One placebo arm participant dropped out due to unrelated personal problems</population>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" spread="0.7"/>
                    <measurement group_id="O2" value="0.92" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Blepharospasm Disability Scale (BDS) Change at 3 Months</title>
        <description>% BDS change at 3 months. The BDS is a quality of life scale ranging from 0 (no symptoms) to 26 (maximum impact of symptoms on quality of life). The questions are specific for impairment related to blepharospasm. We compared the percentage change over three months in the active and placebo arms.</description>
        <time_frame>baseline to 3 months</time_frame>
        <population>One placebo arm participant discontinued study due to unrelated personal problems</population>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>AH-8 containing topical intervention</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>topical intervention WITHOUT AH-8</description>
          </group>
        </group_list>
        <measure>
          <title>% Blepharospasm Disability Scale (BDS) Change at 3 Months</title>
          <description>% BDS change at 3 months. The BDS is a quality of life scale ranging from 0 (no symptoms) to 26 (maximum impact of symptoms on quality of life). The questions are specific for impairment related to blepharospasm. We compared the percentage change over three months in the active and placebo arms.</description>
          <population>One placebo arm participant discontinued study due to unrelated personal problems</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.89" spread="37.3"/>
                    <measurement group_id="O2" value="32.32" spread="31.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>AH-8 containing topical intervention</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>topical intervention WITHOUT AH-8</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>eyelid irritation</sub_title>
                <description>4 subjects (2 active arm and 2 placebo arm) experience minor self-limited eyelid irritation. Ophthalmology consultation was obtained in all cases. No change in the study procedure was needed.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Codrin Lungu, MD</name_or_title>
      <organization>Office of the Clinical Director, NINDS, NIH</organization>
      <phone>301-496-5295</phone>
      <email>lunguci@ninds.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

